Slide Lecture: Therapeutic benefit of baseline PSA: Lower baseline PSA is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial

BERKELEY, CA USA (UroToday.com) - Presented by Leonard Gomella, MD, Clinical Director Jefferson Kimmel Cancer Center Network, Philadelphia, PA USA

Leonard Gomella, MD is the Bernard W. Godwin Professor of Prostate Cancer; Chairman, Department of Urology; Clinical Director Jefferson Kimmel Cancer Center Network; Philadelphia, PA USA.